Latest news with #AbbottIndia
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
These 5 pharma stocks can fall up to 12% as technical charts flag caution
Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for. Premium Rex Cano Mumbai Listen to This Article Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma are the 5 pharma stocks that have flagged a caution signal on the technical charts. Technically, these 5 stocks have seen a negative crossover of the key momentum oscillators like - the Relative Strength Index (RSI), Stochastic Slow or the Moving Average Convergence-Divergence (MACD) on the daily scale. Negative crossover of key momentum oscillators, coupled with violation of key support levels tends to weigh on the stock sentiment. Here's a detailed technical analysis of each of these 5 stocks - Abbott India, Aurobindo Pharma, Cipla, Dr Lal
&w=3840&q=100)
Business Standard
15-05-2025
- Business
- Business Standard
Abbott India Q4 results: Profit up 28% at ₹367 crore, revenue rises 11.5%
Abbott India's Q4FY25 profit grew 28% year-on-year to ₹367 crore on stronger sales, with revenue at ₹1,605 crore and a final dividend of ₹475 per share announced New Delhi Abbott India on Thursday reported a 28 per cent rise in profit after tax (PAT) to ₹367 crore for the fourth quarter ended 31 March 2025, supported by increased sales. The pharmaceutical company had posted a net profit of ₹287 crore in the January–March quarter of the previous financial year. Revenue from operations climbed to ₹1,605 crore in Q4FY25, up from ₹1,439 crore in the same period last year, the company stated in a regulatory filing. For the full financial year ended 31 March 2025, Abbott India reported a net profit of ₹1,414.44 crore, marking a 17.7 per cent increase from ₹1,201.22 crore in FY24. Annual revenue rose to ₹6,409 crore in FY25, compared with ₹5,849 crore in the previous year. The company's board has recommended a final dividend of ₹475 per equity share of face value ₹10 for the financial year ended 31 March 2025, subject to shareholder approval. Shares of Abbott India closed marginally higher at ₹30,371.20 each on the BSE. Total expenses for Q4FY25 increased by 6 per cent to ₹1,197.90 crore, compared to ₹1,130.10 crore in the corresponding quarter of the previous year. Total income for FY25 stood at ₹6,684.70 crore, up from ₹6,097.18 crore in FY24, reflecting a relatively flat growth trajectory.
Reuters
15-05-2025
- Business
- Reuters
Abbott India's quarterly profit climbs 28% on strong demand
May 15 (Reuters) - Drugmaker Abbott India ( opens new tab reported a 28% rise in fourth-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications. The company, known for its PediaSure nutrition drink, reported a profit of 3.67 billion rupees ($43 million) for the quarter ended March 31, up from 2.87 billion rupees a year ago. Revenue from operations climbed 11.5% to 16.05 billion rupees. For further highlights, click. Anti-diabetic, cardiovascular and gastrointestinal drugs, which form a major chunk of Abbott India's drugs portfolio, saw the highest demand during the quarter, Elara Capital said. Moreover, strong demand for Rybelsus, the oral version of Novo Nordisk's ( opens new tab blockbuster weight-loss drug semaglutide distributed by Abbott in India, also boosted sales, analysts said. Peer JB Chem and Pharma also reported higher quarterly profit on strong demand for its gastrointestinal drugs. PEER COMPARISON * Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell ** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT JANUARY TO MARCH STOCK PERFORMANCE -- All data from LSEG -- $1 = 85.4620 Indian rupees
Time of India
05-05-2025
- Health
- Time of India
Stay healthy year-round: Boost your immunity with Vitamin C
Vitamin C, also known as ascorbic acid, is one of the essential micronutrients that plays a crucial role in supporting immunity. 1-3 Research indicates that an effective amount of Vitamin C can reduce cold and flu symptoms by 85% and reduce sick days by 30% 4,5 . However, our body does not produce Vitamin C naturally, and it must be acquired through food or supplements 2 . Prof. Dr Ketan Mehta, Senior Consulting Physician, Suchak Hospital, Mumbai says, 'Pollution and modern lifestyles can harm our cells and weaken our immunity. Vitamin C is a powerful antioxidant that protects cells from the damage caused by free radicals, thereby reducing inflammation and boosting the body's ability to fight diseases.' Poll Have you ever experienced a Vitamin C deficiency? Yes No How to get enough Vitamin C? A balanced diet with fruits and vegetables rich in Vitamin C can enhance your immune system. Citrus fruits like oranges, lemons, tomatoes, guava, amla (Indian gooseberry), and vegetables like bell peppers, broccoli and cauliflower are great sources of Vitamin C 2,8 . However, some groups of people are at higher risk due to shortage of Vitamin C. These include the elderly, individuals with alcohol and drug dependencies, smokers, people who follow trendy diets and people with malabsorption or certain acute and chronic diseases 2 . Taking Vitamin C as recommended by your doctor can help maintain healthy levels. As per a survey conducted by IPSOS and Abbott, about 50% of consumers consider vitamin supplements for preventing illness, especially women (56%) and younger adults aged 36 – 45 (59%) 1 . A study conducted in India found that 74% of elderly adults in North India and 46% in South India have a Vitamin C deficiency 6 . Vitamin C inadequacy is often associated with scurvy, infections, anemia, slow healing of wounds, and bleeding gums. 7 Dr Parag Sheth, Regional Director, Medical & Regulatory Affairs, Abbott India, said, 'Vitamin C is an essential nutrient that offers numerous health benefits. It helps improve symptoms of seasonal infections, such as cold and flu. In addition to helping boost immunity, Vitamin C has other benefits, like collagen formation needed for healthy skin, enhancing iron absorption, and promoting the healing of wounds and bleeding gums. Despite its importance, many individuals do not get enough Vitamin C.' Regular intake of this essential micronutrient in your diet and ensuring you meet the recommended intake during specific health conditions can contribute to your well-being. It is advised to consult your doctor before starting any supplementation, especially, if you have any health conditions. References - IPSOS Survey National Institutes of Health (NIH). Vitamin C. Fact Sheet for Health Professionals. Carr AC, Maggini S. Vitamin C and Immune Function . Nutrients. 2017 Nov 3;9(11):1211. doi: 10.3390/nu9111211. PMID: 29099763; PMCID:PMC5707683 Gorton, Kelly Jarvis, The effectiveness of vitamin C in preventing and relieving the symptoms of virus-induced respiratory infections, Journal of Manipulative and Physiological Therapeutics, Volume 22, Issue 8,1999. Anderson TW, Reid DB, Beaton GH. Vitamin C and the common cold: a double-blind trial. Can Med Assoc J. 1972 Sep 23;107(6):503-8. PMID: 5057006; PMCID: PMC1940935. Ravindran, R.D.; Vashist, P.; Gupta, S.K.; Young, I.S.; Maraini, G.; Camparini, M.; Jayanthi, R.; John, N.; Fitzpatrick, K.E.; Chakravarthy, U.; et al. Prevalence and risk factors for vitamin C deficiency in north and south India: A two centre population based study in people aged 60 years and over. PLoS ONE 2011, 6, e28588. Chambial, S., Dwivedi, S., Shukla, K. K., John, P. J., & Sharma, P. (2013). Vitamin C in disease prevention and cure: an overview. Indian journal of clinical biochemistry: IJCB, 28(4), 314–328. Combs, G. F. 'Vitamin C.' The Vitamins: Fundamental Aspects in Nutrition and Health, 4th ed., Elsevier Academic Press, Burlington (MA), 2008, pp. 246–253. NOTE: Issued in public interest by Abbott for general awareness, for which the author has been engaged by Abbott. Information is based on the author's professional experience and scientific references and is not a substitute for doctor's advice or recommendations from Abbott. Please consult your doctor for more information & advice. The article has been produced on behalf of Abbott by Times Internet's Spotlight Team. The information mentioned in this document is only suggestive/ for patient education and shall not be considered as a substitute for doctor's advice or recommendations from Abbott. Please consult your doctor for more information.
Time of India
22-04-2025
- Business
- Time of India
Novo Nordisk to phase out key drug, insulin cos spot big biz opportunity
As Novo Nordisk prepares to phase out some forms of its human premix insulin brand Mixtard-a move seen overlapping with its planned launch of weight-loss drug Wegovy in India-other top insulin makers are rushing to ramp up production capacity to bridge the potential demand-supply gap the move is expected to create, said top company executives. The Danish pharma major, the maker of semaglutide blockbusters Ozempic and Wegovy, is planning to retire a range of insulin formulations available in easy-to-use disposable pen and cartridge forms by the end of this year. This would include human insulin in penfill and flexpen, including Mixtard 30 Penfill and Flexpen, Actrapid Penfill and Flexpen, Insulatard Penfill and Flexpen, and Mixtard 50 Penfill over the next six months. It will also phase out insulin brand Levemir in FlexPen and Xultophy FlexTouch (Insulin + GLP1). The company recently informed Abbott India about this planned phase-out, according to a document accessed by ET. Abbott is the marketing partner for Novo's insulin. Confirming the development, a Novo Nordisk spokesperson said, "In order to meet increasing patient demand and ensure a stable supply of our medicines, we have decided to consolidate our insulin portfolio, as this will create space needed in our global manufacturing network. Hence, in this process, we are phasing out the penfill." However, the company said it is not discontinuing Mixtard in India and "it will continue to be available in vials". The company did not provide any details on specific brands. "Along with it, other forms of insulins, including human insulins from Novo Nordisk, will continue to be available in vials and devices for patients across India," the spokesperson said. "With the decision, we strive not to leave any patients without alternative treatment options, either from Novo Nordisk or other companies. It is important to us that the transition to other devices or treatment options is as smooth as possible for patients." The phasing out of the penfill Mixtard creates an opportunity for other human premix insulin makers such as Lupin , Eris, Eli Lilly, Wockhardt and Cadila , said industry insiders. Amit Bakshi, MD, Eris Lifesciences , which is ramping up capacity to produce penfill insulin said, "Our strategy is to make sure how we are available through and through and how we can ramp up manufacturing." However, according to him the transition phase may be a "small level of emergency", as a lot of hoarding has been happening in the last couple of months after the news has been out, with several large stockists and patients increasing their stock. "We may not be able to take on all of the demand immediately but are planning to take 60-70% of it."
